WilmerHale Represents Summit Therapeutics in $25M Private Placement

WilmerHale Represents Summit Therapeutics in $25M Private Placement

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
WilmerHale represented Summit Therapeutics plc—a biopharmaceutical company focused on the discovery, development and commercialization of new mechanism antibiotics—in a private placement of 15,625,000 of its American Depositary Shares to the investor, Robert W. Duggan. Summit received $25 million in aggregate gross proceeds from the private placement, before expenses. The transaction signed on December 14, 2018 and closed on January 9, 2019, following the approval of Summit’s shareholders.

The WilmerHale team representing Summit consisted of Brian Johnson, Scott Lunin and Chip McCorkle.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel